Vanda Pharmaceuticals Inc. (VNDA) Stock Price & Analysis
Vanda Pharmaceuticals Inc. (VNDA) closed at USD 4.24 on Thursday, October 15, 2026, up 0.47% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 4.22; the Oct 15, 2026 session ranged USD 4.01–4.31 on volume of 1,045,972 shares. Market capitalization is $256.36M, with a 52-week range of USD 4.01–9.94 (NGM). Source: Nexqual, retrieved October 16, 2026 at 05:22 UTC.
Also available as compact Markdown for AI agents: nexqual.com/VNDA.md
Key facts (VNDA)
- Analysts: Buy (mean 2.20 on a 1–5 scale) (5 analysts), mean target USD 11.75 (range 5.75–20).
- Total return with dividends: 1Y -19.5% vs S&P 500 +18.1%; 5Y -77.0% vs S&P 500 +85.1%.
- Next earnings: 2026-11-04, EPS estimate USD -0.68, revenue estimate $69.1M.
Analysts (VNDA)
Consensus Buy (mean 2.20 on a 1–5 scale), 5 analysts; mean target USD 11.75 (low 5.75, high 20).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-05 | HC Wainwright & Co. | Reiterated | Buy | $20 |
| 2026-09-23 | Oppenheimer | Initiated | Outperform | $10 |
| 2026-08-10 | B. Riley Securities | Target lowered | Buy | $17 → $12 |
| 2026-08-10 | HC Wainwright & Co. | Target lowered | Buy | $21 → $20 |
Total return (dividends reinvested) (VNDA)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | -19.5% | -77.0% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -19.6% | -25.4% |
| Volatility (annualized) | 78.6% | 55.8% |
| Max drawdown | -55.9% (Mar 2026→Oct 2026) | -81.5% (Oct 2021→Nov 2023) |
Key Statistics (as of October 16, 2026 at 05:22 UTC)
| Price | USD 4.24 |
|---|---|
| Change | ▲ 0.47% (up) |
| Previous Close | USD 4.22 |
| Open | USD 4.04 |
| Day Range | USD 4.01 – 4.31 |
| 52-Week Range | USD 4.01 – 9.94 |
| Volume | 1,045,972 shares |
| Market Cap | $256.36M |
| Exchange | NGM |
Technical Analysis (VNDA)
Nexqual's technical model rates VNDA "SELL" based on 2 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:22 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 25.77 (oversold) |
| vs SMA50 | Below (USD 5.05) |
| MACD | -0.24 (negative) |
Analyst Ratings (VNDA)
Wall Street analysts rate VNDA "Buy" based on 5 analysts, with a mean price target of USD 11.75 (range USD 5.75–20), per Nexqual as of October 16, 2026 at 05:22 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 11.75 |
| High Target | USD 20 |
| Low Target | USD 5.75 |
| Buy / Hold / Sell | 4 / 1 / 0 |
Earnings (VNDA)
| Next Earnings Date | 2026-11-04 |
|---|---|
| Revenue Estimate | $69.12M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -1.04 vs est -0.59 ▼ miss |
| 2026-03-31 | USD -0.82 vs est -0.69 ▼ miss |
| 2025-12-31 | USD -2.39 vs est -1.33 ▼ miss |
| 2025-09-30 | USD -0.38 vs est -0.45 ▲ beat |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financials & Fundamentals (VNDA)
| Total Revenue | $215.72M |
|---|---|
| Revenue Growth (latest quarter, YoY) | -3.90% |
| Gross Margin | +93.74% |
| Operating Margin | -126.28% |
| Profit Margin | -127.41% |
| ROE | -77.81% |
| Debt / Equity | 0.1 |
| Current Ratio | 1.61 |
| Total Cash | $170.03M |
| Total Debt | $22.83M |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financial Health Score (VNDA)
Nexqual rates Vanda Pharmaceuticals Inc.'s overall financial health "Mixed" across five dimensions, as of October 16, 2026 at 05:22 UTC.
| Growth | Solid — Revenue +9% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $170M cash vs $23M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$142M (TTM) |
| Efficiency | Critical — ROE -78%, ROA -22.4% |
Ownership (VNDA)
| Insider Ownership | +6.78% |
|---|---|
| Institutional Ownership | +87.90% |
| Shares Outstanding | 60.46M |
| Float | 46.78M |
| Short % of Float | +13.59% |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Leadership (VNDA)
Vanda Pharmaceuticals Inc. is led by Mihael H. Polymeropoulos (age 65), Founder, President, CEO & Chairman of The Board, per Nexqual as of October 16, 2026 at 05:22 UTC.
| Founder, President, CEO & Chairman of The Board | Mihael H. Polymeropoulos (age 65) |
|---|---|
| Senior VP, CFO & Treasurer | Kevin Patrick Moran (age 41) |
| Senior VP & Chief Marketing Officer | Joakim Wijkstrom (age 59) |
| Senior Vice President of Business Development | Gunther Birznieks (age 56) |
| Senior Vice President & Medical Director | Christos Polymeropoulos |
Major Backers & Investors (VNDA)
Notable institutional backers of Vanda Pharmaceuticals Inc. include AQR Capital Management, LLC, Renaissance Technologies, AIGH Capital Management LLC, according to Nexqual as of October 16, 2026 at 05:22 UTC.
Active Investors
| Investor | Stake |
|---|---|
| AQR Capital Management, LLC | 5.78% |
| Renaissance Technologies | 5.69% |
| AIGH Capital Management LLC | 3.38% |
| Acadian Asset Management. LLC | 3.17% |
| Millennium Management | 2.65% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 17.31% |
| State Street | 8.78% |
| Vanguard Group | 8.24% |
| Dimensional Fund Advisors | 2.86% |
| Geode Capital | 2.45% |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:22 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt